Acute symptomatic osteoporotic thoracolumbar compression fracture (ASOTLF) can lead to chronic low back pain, kyphosis deformity, pulmonary dysfunction, loss of mobility, and even life-threatening complications. Vertebral augmentation is currently the mainstream treatment method for this condition. In 2019, the Editorial Board of Chinese Journal of Trauma and the Spinal Trauma Group of Orthopedic Surgeons Branch of Chinese Medical Doctor Association collaboratively led the development of Clinical guideline for vertebral augmentation for acute symptomatic osteoporotic thoracolumbar compression fractures. Six years later, with advances in clinical diagnosis and treatment techniques as well as accumulating evidence in related fields, the 2019 guideline requires updating. To this end, the Spinal Trauma Group of Orthopedic Surgeons Branch of Chinese Medical Doctor Association, the Spinal Health Professional Committee of China Human Health Science and Technology Promotion Association, and the Minimally Invasive Orthopedics Professional Committee of Shaanxi Medical Doctor Association have organized experts in the field to develop the Clinical guideline for vertebral augmentation of acute symptomatic osteoporotic thoracolumbar compression fractures ( version 2025) , based on the latest evidence-based medical researches. This guideline incorporates 3 recommendations retained from the 2019 version with updated strength of evidence, along with 12 new recommendations. It provides recommendations from six aspects of diagnosis, pain management, treatment option selection, prevention of postoperative complications, anti-osteoporosis therapy, and postoperative rehabilitation, aiming to provide a reference for standard treatment of vertebral augmentation for ASOTLF in hospitals at all levels.

The paper reports a 32-year-old female acute myeloid leukemia patient who developed graft-versus-host disease after paternal hematopoietic stem cell transplantation, which subsequently led to renal thrombotic microangiopathy. She subsequently required a kidney transplant from the same donor 5 years later due to renal failure. Considering that both the bone marrow and kidney were from the same donor and the recovery of renal function was favorable, immunosuppressive therapy was discontinued after a short course of anti-rejection treatment, with maintained stable kidney function. This case suggests that under the condition of high chimerism, allogeneic hematopoietic stem cell transplantation and kidney transplantation from the same donor can achieve immune tolerance, potentially improving solid organ transplantation success rate. The findings provide a novel therapeutic approach for solid organ transplantation following allogeneic hematopoietic stem cell transplantation.

Objective:To evaluate the safety and early-to-mid-term efficacy of Cheatham-Platinum (CP) covered stent in treating primary coarctation of the aorta (COA) in children.Methods:?A retrospective self-controlled study was conducted on 20 pediatric patients with primary COA who underwent CP covered stent implantation at the Department of Pediatric Cardiology, Guangdong Provincial People′s Hospital, between January 2006 and December 2024. Clinical baseline characteristics, procedural details, and postoperative follow-up records were collected. Changes in aortic pressure gradients before and after the procedure, as well as the complication rates, were assessed. Comparisons between pre-and post-operative parameters were performed using paired Student′s t-tests and rank sum test. Results:Among the 20 patients, 14 were males and 6 were females, with the age of 12 (11, 13) years and the weight of 43 (36, 49) kg. All of the patients underwent successful implantation of CP-covered stents, with a technical success rate of 100%. The immediate peak gradient across the coarctation segment decreased significantly from 49 (33, 58) mmHg (1 mmHg=0.133 kPa) preoperatively to 3 (0, 5) mmHg postoperatively ( Z=3.92, P<0.001). The narrowest vessel diameter increased from (5.6±3.2) mm preoperatively to (16.9±5.4) mm postoperatively ( t=14.73, P<0.001). Following stent implantation, all patients exhibited a significant reduction in blood pressure, with left upper arm systolic blood pressure decreasing from(141±19) mmHg preoperatively to (122±11) mmHg postoperatively ( t=4.47, P<0.001). Immediate complications occurred in 3 cases: one pseudoaneurysm, one left subclavian artery occlusion, and one access site hematoma. During a follow-up period of 2 (1, 3) years, 16 patients maintained blood pressure within the normal range, while 4 had residual hypertension. Restenosis occurred in 3 patients: 1 patient underwent re-dilation at 24 months postoperatively; and the other 2 patients, who exhibited an upper-to-lower limb systolic blood pressure gradient <20 mmHg, did not require intervention at the time of reporting. All stents remained well-positioned. Follow-up CT angiography at 1 year in 8 patients demonstrated stent patency without evidence of fracture or aneurysm. Conclusion:CP-covered stent demonstrates high safety and favorable short-to-mid-term efficacy in treating primary COA in children.

Acute symptomatic osteoporotic thoracolumbar compression fracture (ASOTLF) can lead to chronic low back pain, kyphosis deformity, pulmonary dysfunction, loss of mobility, and even life-threatening complications. Vertebral augmentation is currently the mainstream treatment method for this condition. In 2019, the Editorial Board of Chinese Journal of Trauma and the Spinal Trauma Group of Orthopedic Surgeons Branch of Chinese Medical Doctor Association collaboratively led the development of Clinical guideline for vertebral augmentation for acute symptomatic osteoporotic thoracolumbar compression fractures. Six years later, with advances in clinical diagnosis and treatment techniques as well as accumulating evidence in related fields, the 2019 guideline requires updating. To this end, the Spinal Trauma Group of Orthopedic Surgeons Branch of Chinese Medical Doctor Association, the Spinal Health Professional Committee of China Human Health Science and Technology Promotion Association, and the Minimally Invasive Orthopedics Professional Committee of Shaanxi Medical Doctor Association have organized experts in the field to develop the Clinical guideline for vertebral augmentation of acute symptomatic osteoporotic thoracolumbar compression fractures ( version 2025) , based on the latest evidence-based medical researches. This guideline incorporates 3 recommendations retained from the 2019 version with updated strength of evidence, along with 12 new recommendations. It provides recommendations from six aspects of diagnosis, pain management, treatment option selection, prevention of postoperative complications, anti-osteoporosis therapy, and postoperative rehabilitation, aiming to provide a reference for standard treatment of vertebral augmentation for ASOTLF in hospitals at all levels.

The paper reports a 32-year-old female acute myeloid leukemia patient who developed graft-versus-host disease after paternal hematopoietic stem cell transplantation, which subsequently led to renal thrombotic microangiopathy. She subsequently required a kidney transplant from the same donor 5 years later due to renal failure. Considering that both the bone marrow and kidney were from the same donor and the recovery of renal function was favorable, immunosuppressive therapy was discontinued after a short course of anti-rejection treatment, with maintained stable kidney function. This case suggests that under the condition of high chimerism, allogeneic hematopoietic stem cell transplantation and kidney transplantation from the same donor can achieve immune tolerance, potentially improving solid organ transplantation success rate. The findings provide a novel therapeutic approach for solid organ transplantation following allogeneic hematopoietic stem cell transplantation.

Objective:To evaluate the safety and early-to-mid-term efficacy of Cheatham-Platinum (CP) covered stent in treating primary coarctation of the aorta (COA) in children.Methods:?A retrospective self-controlled study was conducted on 20 pediatric patients with primary COA who underwent CP covered stent implantation at the Department of Pediatric Cardiology, Guangdong Provincial People′s Hospital, between January 2006 and December 2024. Clinical baseline characteristics, procedural details, and postoperative follow-up records were collected. Changes in aortic pressure gradients before and after the procedure, as well as the complication rates, were assessed. Comparisons between pre-and post-operative parameters were performed using paired Student′s t-tests and rank sum test. Results:Among the 20 patients, 14 were males and 6 were females, with the age of 12 (11, 13) years and the weight of 43 (36, 49) kg. All of the patients underwent successful implantation of CP-covered stents, with a technical success rate of 100%. The immediate peak gradient across the coarctation segment decreased significantly from 49 (33, 58) mmHg (1 mmHg=0.133 kPa) preoperatively to 3 (0, 5) mmHg postoperatively ( Z=3.92, P<0.001). The narrowest vessel diameter increased from (5.6±3.2) mm preoperatively to (16.9±5.4) mm postoperatively ( t=14.73, P<0.001). Following stent implantation, all patients exhibited a significant reduction in blood pressure, with left upper arm systolic blood pressure decreasing from(141±19) mmHg preoperatively to (122±11) mmHg postoperatively ( t=4.47, P<0.001). Immediate complications occurred in 3 cases: one pseudoaneurysm, one left subclavian artery occlusion, and one access site hematoma. During a follow-up period of 2 (1, 3) years, 16 patients maintained blood pressure within the normal range, while 4 had residual hypertension. Restenosis occurred in 3 patients: 1 patient underwent re-dilation at 24 months postoperatively; and the other 2 patients, who exhibited an upper-to-lower limb systolic blood pressure gradient <20 mmHg, did not require intervention at the time of reporting. All stents remained well-positioned. Follow-up CT angiography at 1 year in 8 patients demonstrated stent patency without evidence of fracture or aneurysm. Conclusion:CP-covered stent demonstrates high safety and favorable short-to-mid-term efficacy in treating primary COA in children.

Objectives: This study aimed to explore the influence of depression severity, disease course, treatment status, and other factors on cognitive function in adolescents with depressive disorders. Methods: Participants who met the inclusion criteria were enrolled in the study. Sociodemographic data of each participant were recorded, including age, sex, and family history of mental disorders. Zung’s Self-Rating Depression Scale was used to assess depression status in adolescents. Moreover, P300 and mismatch negativity (MMN) were used to objectively evaluate the participants’ cognitive function. Results: Only 26.8% of the adolescents with depression received standard antidepressant treatment. The latencies of N2 (267.80±23.34 ms), P3 (357.71±32.09 ms), and MMN (212.10±15.61 ms) in the adolescent depression group were longer than those in the healthy control group (p<0.01). Further analysis revealed that the latency of MMN was extended with increased levels of depression in adolescents.The MMN latency was short in participants with depression receiving standardized treatment. Furthermore, the latency of MMN was positively correlated with the severity and duration of depression (correlation coefficients were 0.465 and 0.479, respectively) (p<0.01). Conclusion Receiving standardized treatment and shortening the course of depression can reduce cognitive impairment in adolescents with depression.

Objective:To explore the development and interaction between chronotype and depressive symp-toms among middle school students in Chongqing.Methods:A total of 1208 middle school students(613 in grade 7,595 in grade 10)were surveyed for three follow-ups at 6-month intervals.Periods T1-T3 represented baseline,6 months later,and 12 months later,respectively.Chronotype and depressive symptoms were measured by the Morn-ing and Evening Questionnaire-5(MEQ-5)and the Patient Health Questionnaire-9(PHQ-9).Analyses were per-formed using SPSS 26.0 and Mplus 8.3.Results:The MEQ-5 scores were lower in T1 than in T3,and the scores were lower in T2 than in T1 and T3(F=20.08,P＜0.001),suggesting a fluctuating trend of chronotype shifting to the Evening-type first after baseline and then to the Morning-type.The PHQ-9 scores exhibited a significant differ-ence among the three-time measurements(x2/df=9.77/2,P＜0.01).But pairwise comparisons did not yield any statistically significant findings(P＞0.05).The cross-lagged panel model showed that pathways of Ti MEQ-5 scores negatively predicted Ti+1 PHQ-9 scores(βTi-Ti+1=-0.12/-0.09,P＜0.05)and TiPHQ-9 scores nega-tively predicted Ti+1 MEQ-5 scores(βTi-Ti+1=-0.07/-0.11,P＜0.05).Conclusion:Chronotype and depressive symptoms show some changes in adolescents.The more inclined adolescents are to the Evening-type,the higher the likelihood of depressive symptoms occurring later.The more severe the depressive symptoms,the greater the likeli-hood of a subsequent shift to the Evening-type.

Artemsia argyi Levl.et Vant is a commonly used Chinese herbal medicine and moxibustion raw material plant,so far has more than two thousand years of medicinal history,as one of the most commonly used Chinese medicinal materials.The incopat patent database was used to search the worldwide patent data of the last 20 years,and a total of 25279 argyi related patents were retrieved.The pattern of argyi patents was analyzed from the perspectives of global application trend,main technical fields,national economy composition,applicant ranking,patent value and other aspects by means of graph combination.The analysis shows that the innovation and development of argyi is in the stage of rapid development;The medical,Chinese patent medicine,cosmetics and physiotherapy of argyi are the hot research and development of current technology;There are a large number of patents related to argyi in the world,but they are mainly distributed in China and South Korea.Among them,the number of patents related to argyi in China reaches 20381,far higher than that in other countries,but the number of high-value patents is not very large,and the value and quality of patents are still insufficient compared with other countries.From the perspective of the current development trend of argyi,with the deepening of clinical application recognition and scientific research of argyi,there is a large patent space in the field of argyi.Patent applicants can formulate corresponding patent application strategies according to the global development opportunities,technological development status and existing weaknesses.

The method of scoping review was used to systematically search and sort out the clinical research of oral Chinese patent medicines for ischemic stroke，to understand the scope of relevant research and the distribution of evidence. Three medical catalogs were manually searched to obtain the oral Chinese patent medicines used for ischemic stroke，and 7 databases were retrieved to obtain the clinical research including these oral Chinese patent medicines. Then the clinical evidence results were visualized by description combined with chart analysis. A total of 68 oral Chinese patent medicines were retrieved，and 1 392 articles were included，with 367 published in core journals， involving 35 oral Chinese patent medicines. The research types included randomized controlled trials，cohort studies，case series，case reports，secondary studies，adverse drug reaction reports，pharmacoeconomic evaluations，drug interactions，consensus or guidelines，non-randomized intervention studies and cross-sectional studies，of which randomized controlled trials had the largest number （283， 77.1%），followed by secondary studies and case series （25， 6.7% for each）. Among the 283 randomized controlled trials，there were 159 clinical studies in the acute phase of ischemic stroke，65 in the non-acute phase，and 59 in the unclear phase. Ten intervention control types and 20 outcome index types were summarized. Among them， the composite outcome index and surrogate outcome index were used 217 times （76.7%） and 245 times （86.6%）， respectively，followed by the degree of neurological impairment （three scales）. Future clinical research of oral Chinese patent medicines for ischemic stroke should clarify the stage of the disease，and the research design should specify the advantages of oral Chinese patent medicines intervening in ischemic stroke. Furthermore， publicly-recognized positive controls should be employed，and important clinical outcome indexes should be selected.